Ranolazine

Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) [1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.

Product Specifications

CAS Number

[95635-55-5]

Product Name Alternative

CVT 303; RS 43285-003

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Calcium Channel; Sodium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/ranolazine.html

Purity

99.79

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(NC1=C(C)C=CC=C1C)CN2CCN(CC(O)COC3=CC=CC=C3OC)CC2

Molecular Formula

C24H33N3O4

Molecular Weight

427.54

Precautions

H302, H315, H319, H335

References & Citations

[1]Keating GM. Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris. Drugs. 2013 Jan;73 (1) :55-73.|[2]Wang WQ, et al. Antitorsadogenic effects of ({+/-}) -N- (2,6-dimethyl-phenyl) - (4[2-hydroxy-3- (2-methoxyphenoxy) propyl]-1-piperazine (ranolazine) in anesthetized rabbits. J Pharmacol Exp Ther. 2008 Jun;325 (3) :875-81.|[3]Zacharowski K, et al. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol. 2001 Apr 20;418 (1-2) :105-10.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Launched

Citation 01

Philos Trans R Soc Lond B Biol Sci. 2023 Jun 19;378 (1879) :20220163.|J Invest Dermatol. 2023 Feb;143 (2) :305-316.e5.|Pharmaceutics. 2024 May 29;16 (6) :728.|Theranostics. 2018 Oct 29;8 (19) :5452-5468.